{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:10:14Z","timestamp":1791609014246,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4032-3","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T14:14:46Z","timestamp":1517840086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III\/IV NSCLC in Germany: an observational study"],"prefix":"10.1186","volume":"18","author":[{"given":"Wolfgang","family":"Schuette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried E. E.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Dietel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Zirrgiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Muehlenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"issue":"suppl 5","key":"4032_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1\u2013v27.","journal-title":"Ann Oncol"},{"key":"4032_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","volume":"31","author":"T Li","year":"2013","unstructured":"Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039\u201349.","journal-title":"J Clin Oncol"},{"key":"4032_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"4032_CR4","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.","journal-title":"N Engl J Med"},{"key":"4032_CR5","unstructured":"German Cancer Guidelines. Lungenkarzinom, nicht-kleinzellig (NSCLC). Onkopedia 2016. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/lungenkarzinom-nicht-kleinzellig-nsclc\/@@view\/html\/index.html . Accessed 1 Apr 2016."},{"key":"4032_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/1055-9965.EPI-14-1149","volume":"24","author":"W Schuette","year":"2015","unstructured":"Schuette W, Schirmacher P, Eberhardt WE, et al. EGFR mutation status and first-line treatment in patients with stage III\/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomark Prev. 2015;24:1254\u201361.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"4032_CR7","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","volume":"11","author":"M Reck","year":"2016","unstructured":"Reck M, Hagiwara K, Han B, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. J Thorac Oncol. 2016;11(10):1682\u20139.","journal-title":"J Thorac Oncol"},{"key":"4032_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"4032_CR9","unstructured":"Kris MG, Johnson B, Berry L, et al. Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: results from the lung cancer mutation consortium (LCMC). Sydney, Australia: Presented at the WCLC, 2013. Abstract PL03.07. p. 27\u201331. http:\/\/pic1.cmt.com.cn\/newspic\/files\/%E4%BC%9A%E8%AE%AE%E6%97%A5%E7%A8%8B.pdf . Accessed 29 Jan 2018."},{"issue":"209","key":"4032_CR10","first-page":"ra153","volume":"5","author":"Clinical Lung Cancer Genome Project (CLCGP)","year":"2013","unstructured":"Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5(209):ra153.","journal-title":"Sci Transl Med"},{"key":"4032_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1185\/03007995.2013.860372","volume":"30","author":"A Carrato","year":"2014","unstructured":"Carrato A, Vergnenegre A, Thomas M, McBride K, Medina J, Cruciani G. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-lung study. Curr Med Res Opin. 2014;30:447\u201361.","journal-title":"Curr Med Res Opin"},{"key":"4032_CR12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5603\/ARM.27563","volume":"80","author":"M Knetki-Wroblewska","year":"2012","unstructured":"Knetki-Wroblewska M, Kowalski DM, Zajda K, et al. Gefitinib in patients with advanced non-small-cell lung cancer. Pneumonol Alergol Pol. 2012;80:439\u201349.","journal-title":"Pneumonol Alergol Pol"},{"key":"4032_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12253-013-9715-0","volume":"20","author":"RL Lu","year":"2014","unstructured":"Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Pathol Oncol Res. 2014;20:445\u201351.","journal-title":"Pathol Oncol Res"},{"issue":"Suppl 9","key":"4032_CR14","first-page":"ix400","volume":"23","author":"P-J Souquet","year":"2012","unstructured":"Souquet P-J, Fournel P, Locher C, et al. MUTACT: an observational study of EGFR mutation status and management of patients with non-small cell lung cancer (NSCLC) adenocarcinoma. Ann Oncol. 2012;23(Suppl 9):ix400\u201346. (Abstract 1270P)","journal-title":"Ann Oncol"},{"key":"4032_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169\u201381.","journal-title":"Nat Rev Cancer"},{"key":"4032_CR16","unstructured":"AstraZeneca. IRESSA (Gefitinib) receives marketing authorisation for the treatment of non-small cell lung cancer in Europe [press release]. AstraZeneca UK Ltd. 2009. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2009\/IRESSA-Gefitinib-Receives-Marketing-Authorisation-01072009.html# #. Accessed 1 Apr 2016."},{"key":"4032_CR17","unstructured":"Roche. Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer [press release]. F. Hoffmann-La Roche Ltd. 2011. https:\/\/www.roche.com\/media\/store\/releases\/med-cor-2011-09-01.htm . Accessed 1 Apr 2016."},{"key":"4032_CR18","doi-asserted-by":"publisher","first-page":"S636","DOI":"10.1016\/S0959-8049(11)72456-X","volume":"47","author":"W Eberhardt","year":"2011","unstructured":"Eberhardt W, Thomas M, Graf von der Schulenberg J-M, et al. EGFR mutation testing and first-line treatment of patients with advanced NSCLC and positive EGFR mutation status: results from a German registry. Eur J Cancer. 2011;47:S636.","journal-title":"Eur J Cancer"},{"key":"4032_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4143\/crt.2013.227","volume":"47","author":"JK Lee","year":"2015","unstructured":"Lee JK, Kim DW, Keam B, et al. The impact of molecularly targeted treatment on direct medical costs in patients with advanced non-small cell lung cancer. Cancer Res Treat. 2015;47:182\u20138.","journal-title":"Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T22:45:34Z","timestamp":1660430734000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4032-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4032-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"29 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.The opinion from the Ethics Committee of the coordinating investigator (\u00c4rztekammer Sachsen-Anhalt) was sought for the final study protocol, including the final version of the Informed Consent Form. Notifications were sent to the Ethics Committees of all involved investigators. An Ethics Committee opinion was also sought for any amendment to the protocol in accordance with local requirements.All patients provided written, informed consent.This article does not contain any studies with animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WS reports honoraria from, Roche, Lilly and Boehringer Ingelheim, consulting or advisory roles with Roche, Lilly and Boehringer Ingelheim and travel, accommodation or expenses from Boehringer Ingelheim. PS reports honoraria from AstraZeneca, Novartis, Roche, Amgen and Pfizer and consulting or advisory roles with AstraZeneca, Novartis, Amgen and Pfizer. WE reports honoraria from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Pfizer, Novartis, Roche, Merck, Bristol-Myers Squibb, Amgen, GlaxoSmithKline, Astellas, Bayer, Teva, Merck Serono, Daichi Sankyo and Hexal and consulting or advisory roles with AstraZeneca, Eli Lilly, Boehringer Ingelheim, Novartis, Pfizer, Roche, Merck, Bristol-Myers Squibb, Astellas, Bayer, Teva and Daichi Sankyo. UZ is an employee of iOMEDICO AG. LM is an employee of AstraZeneca. MT reports honoraria from AstraZeneca, Roche, Bristol-Myers Squibb, MSD, Lilly, Novartis and Pfizer and consulting or advisory roles with AstraZeneca, Bristol-Myers Squibb, MSD, Lilly, Novartis and Roche. MD reports no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"135"}}